Aignosis Raises Rs 4 Crore to Expand AI-Assisted Autism Screening Across India

Autism screening in much of India still depends on a shortage of specialist pediatricians and developmental experts concentrated in a handful of major cities, leaving families in smaller towns with little practical access. Aignosis is building a screening tool meant to extend that specialist judgment to places specialists rarely reach.

Aignosis, a Jaipur-based healthtech startup founded by Raksheet Jain and Divyansh Mangal, raised Rs 4 crore in a seed round led by Antler and Nikhil Kamath, with participation from angel investors including Varun Dua and IIMA Ventures. The company has built an AI-assisted platform for autism and developmental screening and has completed its CDSCO regulatory process, receiving Class B certification. Aignosis has completed more than 8,000 screenings to date and is targeting at least 1 lakh screenings by the end of fiscal year 2027, with plans to expand into Punjab, the National Capital Region, Haryana, Tamil Nadu, Jharkhand, Karnataka and Maharashtra.

Why Regulatory Certification Matters More Here Than in Most Healthtech Categories

Securing Class B certification through India's CDSCO regulatory process before this seed round is a meaningfully higher bar than most early-stage healthtech startups clear at this stage, and signals the company built its product with clinical deployment in mind from the outset rather than treating regulatory approval as a later-stage concern. For a screening tool that will influence real developmental-care decisions for children, that regulatory grounding is likely to matter more to government and private healthcare partners than it would for a typical consumer health app.

Why Backing From Antler and Nikhil Kamath Signals Early Conviction

Antler's global accelerator-and-fund model specifically backs very early-stage, often pre-product companies, meaning its participation here reflects conviction in Aignosis's founding team and screening approach even before the startup had built out the scale of clinical validation it has today. Nikhil Kamath's participation, alongside operator-adjacent angel investorslike Varun Dua, adds a layer of India-specific startup-ecosystem credibility that can matter for a healthtech company whose next phase of growth depends heavily on building relationships with government health networks across multiple states.

What This Means for Founders

For founders building regulated healthtech products aimed at underserved geographies in India, Aignosis's approach, securing real regulatory certification and demonstrating thousands of completed screenings before scaling into new states, is a useful model for de-risking a seed-stage healthtech pitch in a category where trust and regulatory legitimacy matter as much as the underlying technology. Founders pursuing a similar expansion across government and private healthcare networks should also note the multi-state rollout plan here, seven new states from a single Jaipur base, as a reminder that distribution into fragmented state-level healthcare systems is often the harder scaling problem relative to the product itself.

Browse the healthtech investor directory for more active funds in Indian clinical and diagnostic technology, read the baseline mechanics of a seed round if the term is new, or explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai